DUBLIN--(BUSINESS WIRE)--The "Alpha-Antitrypsin Deficiency - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
The report provides global market share of AATD i.e., 6 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)] and Rest of World (RoW). In 2016, the global market size of AATD was USD 918.78 million.
According to research, the prevalent cases of AATD was 185,860 in 2016 in 6MM. Among 6MM, United States account for highest prevalent cases of AATD with 113,808 prevalent cases in 2016 followed by Germany.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of AATD from 2016 to 2027 segmented by the US, EU-5 countries and Rest of the World (RoW). The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
This market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for AATD in the US, Europe, and Japan.
- CSL Behring
- LFB Biotechnologies
Key Topics Covered:
1. Report Introduction
2. Alpha Antitrypsin Deficiency Market Overview at a Glance
3. Disease Background and Overview: Alpha Antitrypsin Deficiency
4. Epidemiology and Patient Population
5. Treatment Algorithm
6. Unmet Needs
7. Marketed Drugs
8. Emerging Therapies
9. Alpha Antitrypsin Deficiency: Global Market Analysis
10. Alpha Antitrypsin Deficiency: Country-Wise Market Analysis
11. Grifols Initiatives towards Alpha Anti-trypsin deficiency
12. USFDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)
13. Market Drivers
14. Market Barriers
16. Report Methodology
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5k2sz2/2018?w=4